US Patent Issued to Allogene Therapeutics on March 17 for "Knockdown or knockout of one or more of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to mitigate t cell recognition of allogeneic cell products" (California Inventors)

ALEXANDRIA, Va., March 17 -- United States Patent no. 12,577,283, issued on March 17, was assigned to Allogene Therapeutics Inc. (South San Francisco, Calif.).

"Knockdown or knockout of one or more of TAP2, NLRC5, B2m, TRAC, RFX5, RFXAP and RFXANK to mitigate t cell recognition of allogeneic cell products" was invented by Michael Thomas Bethune (Castro Valley, Calif.), Eric Hans Gschweng (Oak Park, Calif.), Thomas John Van Blarcom (Oakland, Calif.), Cesar Adolfo Sommer (San Mateo, Calif.) and Michael C Yi (Foster City, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are engineered immune cells and populations thereof for administration to patients to treat cancer (e.g., solid tumors or ...